

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KINGWORLD MEDICINES GROUP LIMITED**  
**金活醫藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code : 01110)

**INSIDE INFORMATION**

**BUSINESS UPDATE**

This announcement is made by Kingworld Medicines Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the qualification review of the overseas flagship store of Tmall Global “Kingworld Health Family” (天貓國際金活健康之家海外旗艦店) (the “**Flagship Store**”) has been completed and the Flagship Store is expected to be officially launched at the end of January 2021.

The Flagship Store will be operated by the Company’s wholly-owned subsidiary, Kingworld Medicine Healthcare Limited (金活藥業健康發展有限公司). It is intended that the Flagship Store will serve as a business-to-consumer cross-border online sales platform and offer pharmaceutical and healthcare products registered in Hong Kong, including well-known Hong Kong cough products (including convenience packs), eye care products, digestive aids, nourishing products, nutritional products and other well-known pharmaceutical and healthcare products to consumers directly.

The Board believes that the launch of the Flagship Store will increase brand awareness of the Group, deepen market penetration, and satisfy the demand for high-quality pharmaceutical and healthcare products of consumers and will be beneficial to the Company and its shareholders as a whole.

By order of the Board  
**Kingworld Medicines Group Limited**  
**Zhao Li Sheng**  
*Chairman*

Hong Kong, 11 January 2021

*As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Zhao Li Sheng, Ms. Chan Lok San, and Mr. Zhou Xuhua, and three independent non-executive Directors, namely Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.*